Twist Bioscience Corp's 2025 guidance doesn't include MRD growth, indicating uncertainty. Express Genes expects a 50% gross margin by Q4. Minimal exposure to NIH budgets gives a competitive edge. Next-gen sequencing innovations benefit revenue.